It has been reported that Novo Nordisk may have inadvertently allowed generics of its GLP-1 agonist semaglutide, the active ingredient in diabetes therapy Ozempic and obesity drug Wegovy, into the ...

Faced with the prospect of tariffs on imported medicines threatened by the Trump administration, Indian drugmaker Hikma has said it will spend $1 billion to expand its manufacturing and R&D operations ...